Abstract:To the Editor: Mycobacteria are commonly characterized by positive acid-fast staining. Most mycobacterial species belong to the nontuberculous mycobacteria (NTM), excluding species in the Mycobacterium tuberculosis complex and M. leprae. Both M. tuberculosis and NTM can induce pulmonary infection with similar symptoms and pulmonary radiographic findings (1). These similarities have led to difficulty in distinguishing these infections clinically. As in many developing countries, the acid-fast stain is the only bacteriologic basis for diagnosing tuberculosis (TB) in primary health care institutions in China, where facilities are limited for M. tuberculosis culture, strain identification, and drug resistance detection. Thus, NTM is easily misdiagnosed as M. tuberculosis, and multidrug-resistant (MDR) TB is unable to be accurately identified. Patients with misdiagnosed TB usually are treated with the standard anti-TB regimens recommended by the Chinese government (i.e., 2HRZE/4HR [2 months of isoniazid (INH), rifampin (RIF), pyrazinmid, and ethambutol, followed by 4 months of INH and RIF 1 time daily] and 2H3R3Z3E3/4H3R3 [2 months of INH, RIF, pyrazinamide, and ethambutol followed by 4 months of INH and RIF 3 times weekly]) (2), which often results in treatment failures. Misdiagnosis is a key hurdle for effective prevention and treatment of TB (3–5). To evaluate the effect of misdiagnosis on TB prevention, we determined the proportion of patients with MDR TB and NTM infection in primary health care institutions in Zhejiang Province, China. Our findings would be useful for improving TB prevention and treatment. During 2011–2012, sputum samples from 13,882 patients suspected of having TB in 8 counties in Zhejiang Province were used to culture mycobacteria. Each sample was seeded onto 2 pieces of Lowenstein-Jensen medium. A total of 1,410 samples grew mycobacteria confirmed as acid-fast bacilli by using Ziehl-Neelsen staining. The 1,410 samples were further identified by using the Mycobacteria Identification Array Kit (CapitalBio, Beijing, China). The kit contains 17 types of bacilli-specific 16S rRNA probes (i.e., M. tuberculosis complex, M. avium, M. intracellulare, M. gilvum, M. xenopi, M. smegmatis, M. aurum, M. terrae, M. gordonae, M. chelonae/abscessus, M. phlei, M. scrofulaceum, M. fortuitum, M. szulgai, M. ulcerans, M. marinum, and M. kansasii). With this method, M. tuberculosis and NTM can be distinguished, and the species of NTM can be identified (6–8). Of 1,410 positive strains, we identified 1,332 (94.5%) as M. tuberculosis and 78 (5.5%) as NTM. NTM strains were further identified as follows: M. intracellulare, 39 isolates; M. chelonae/abscessus, 12 isolates, M. kansasii, 13 isolates; M. avium, 3 isolates; M. fortuitum, 4 isolates; and M. scrofulaceum and M. szulgai, 1 isolate each. For 5 isolates, strain could not be classified. We detected drug resistance of 1,332 M. tuberculosis strains using a Tuberculosis Drug Resistance Detection Array Kit (CapitalBio) (9). The mutant points for RIF resistance were identified as follows: rpoB/C531G, C531T, CG531AC, A526C, A526G, A526T, C526A, C526G, C526T, T533C, A516G, A516T, G516T, T511C, T511G, C513A, A513T, and C522T (Table). Moreover, the kit contained 5 mutant points for INH resistance, including katG (G315A, G315C, G315T, and C315) and inhA (C-15T) (Table). Of 1,332 M. tuberculosis strains, we identified 1,115 (83.7%) RIF/INH-sensitive strains, 88 (6.6%) MDR TB strains, 83 (6.2%) INH-resistant strains, and 47 (3.5%) RIF-resistant strains. Of the 1,410 positive strains, 88 (6.2%) were MDR M. tuberculosis strains. Table Gene mutations of 214 drug-resistant tubercle bacilli, Zhejiang Province, China, 2011–2012 The epidemiology of TB in Zhejiang Province reflects the situation in China and some developing countries (10). The clinical diagnosis and treatment of >80% TB cases in China is performed mainly by primary health care institutions. However, almost 80% of these medical institutions do not have the capability to culture M. tuberculosis, detect drug resistance, and identify strains (7). Of 1,410 strains obtained from the patients in 8 counties of Zhejiang Province, 218 (15.5%) were MDR TB, INH resistant, and RIF resistant. These affected patients could not be effectively treated with the national standard regimens. Specifically, 88 patients with MDR TB would be at risk for extensively drug-resistant TB, and 83 patients with INH-resistant TB and 47 with RIF-resistant TB would be at risk for MDR TB. In addition, we identified 78 (5.5%) NTM strains. With the acid-fast stain, these illnesses would be misidentified as TB and, in most instances, also would be reported as treatment failures. Clearly, accurate diagnosis provided by the technologies used in this study for distinguishing NTM and M. tuberculosis, Mycobacterium strain identification, and drug-resistance detection would increase the cure rate and effectively prevent TB epidemics. For INH resistance, katG315 was a main mutant point of the M. tuberculosis strain; 140 (81.4%) of the 172 INH-resistant mutations were related to katG315. For RIF resistance, rpoB531 was a main mutant point; 84 (60.0%) of 140 RIF-resistant mutations were associated with rpoB531. Therefore, in future studies, more attention should be paid to the molecular epidemiology of katG315 and rpoB531. In conclusion, using the techniques for M. tuberculosis culture, Mycobacterium strain identification, and drug-resistance detection is necessary. It should be urgently pursued for accurate TB diagnosis in primary health care institutions in China to improve the prevention, treatment, and control of TB.

Case report: A 9-year systematic treatment failure of a pulmonary tuberculosis patient

A Clinical Study on the Infection of Multiple-Drug Resistance Pulmonary Tuberculosis and L-forms of Mycobacterium Tuberculosis

Longitudinal Molecular Epidemiological Study of Multidrug Resistant Tb and Transition to Extensively Drug Resistance in Eastern Rual China

The past, present and future of tuberculosis treatment.

Genetic factors associated with acquired phenotypic drug resistance and its compensatory evolution during tuberculosis treatment

Distinguishing Nontuberculous Mycobacteria from Multidrug-Resistant Mycobacterium Tuberculosis, China

Impact of Genotypic and Phenotypic Resistance to Second-Line Anti-Tuberculosis Drugs on Treatment Outcomes in Multidrug-Resistant Tuberculosis in China.

[Emergence of a multidrug-resistant tuberculosis through inadequate treatment of isoniazid monoresistance]

Clinical application of whole-genome sequencing in the management of extensively drug-resistant tuberculosis: a case report

Additional Drug Resistance for Mycobacterium Tuberculosis During Turnaround Time for Drug-Susceptibility Testing in China: A Multicenter Observational Cohort Study

Treatment outcomes of the standardized regimens for patients with multidrug-resistant pulmonary tuberculosis in Wenzhou during 2013 to 2015

Drug resistance characteristics and cluster analysis of M. tuberculosis in Chinese patients with multiple episodes of anti-tuberculosis treatment

In Vivo Evolution of Drug-Resistant Mycobacterium Tuberculosis in Patients During Long-Term Treatment

Risk factors for drug resistance in pulmonary tuberculosis inpatients.

Impact of delayed diagnosis and treatment on tuberculosis infection within families: A case report

Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing.

Prediction of treatment outcomes for multidrug-resistant tuberculosis by whole-genome sequencing

Treatment Outcomes of Multidrug-Resistant Tuberculosis Patients in Zhejiang, China, 2009–2013

Tuberculosis treatment failure associated with evolution of antibiotic resilience

Efficacy and Effect of Free Treatment on Multidrug-Resistant Tuberculosis.

Treatment Outcomes and Associated Influencing Factors Among Patients with Rifampicin-Resistant Tuberculosis: A Multicenter, Retrospective, Cohort Study in China